The launch of at least 20 new formulations of analgesics to treat acute pain over the next few years will drive 3% growth in the acute pain drug market, according to a new report.
The report from Decision Resources believes the uptake of the new drugs will boost annual market share in the US, France, Germany, Italy, Spain, the UK and Japan.
The report, entitled Acute Pain, reveals that besides Merck’s novel telcagepant and PriCara/Grunenthal’s Nucynta, nearly all emerging therapies expected to be launched until 2018 are reformulations of conventional analgesics that include fentanyl, oxycodone, diclofenac and bupivacaine.
Decision Resources analyst Sandra Chow said that over the next few years, at least 20 new formulations of analgesics for acute pain will launch in one or more of the seven major markets under study.
“The uptake of these new formulations will be driven by the much-needed improvements they offer in safety, tolerability, abuse deterrence and/or ease of use compared with available products,” Chow said.
The report also identifies the key patient segments targeted by drug developers, includeing severe post-operative pain and breakthrough cancer pain.